Biogen (BIIB) Stock Forecast & Price Target

Compare

4,905 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BIIB Analyst Ratings

Moderate Buy

12 Buy

14 Hold

0 Sell

Based on 26 analysts giving stock ratings to

Biogen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$166.20

▲(11.66% Upside)

Based on 26 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $166.20 with a high forecast of $224.00 and a low forecast of $118.00. The average price target represents a 11.66% change from the last price of $148.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"117":"$117","144":"$144","171":"$171","198":"$198","225":"$225"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":224,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$224.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":166.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$166.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$118.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[117,144,171,198,225],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,139.63,146.12,152.60999999999999,159.1,165.59,172.07999999999998,178.57,185.06,191.55,198.04,204.53,211.01999999999998,217.51,{"y":224,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,139.63,141.67384615384614,143.7176923076923,145.76153846153846,147.8053846153846,149.84923076923076,151.8930769230769,153.93692307692308,155.98076923076923,158.02461538461537,160.06846153846152,162.1123076923077,164.15615384615384,{"y":166.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,139.63,137.96615384615384,136.3023076923077,134.63846153846154,132.9746153846154,131.31076923076924,129.6469230769231,127.98307692307692,126.31923076923077,124.65538461538462,122.99153846153845,121.3276923076923,119.66384615384615,{"y":118,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":204.76,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.79,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$224.00

Average Price Target$166.20

Lowest Price Target$118.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sumant Kulkarni

Canaccord Genuity

$220

Buy

47.81%

Upside

Reiterated

09/12/25

Canaccord Genuity Keeps Their Buy Rating on Biogen (BIIB)Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $220.00 price target on Biogen (NASDAQ: BIIB).

Veda Pharmyne

TR | OpenAI - 4o

$152→$170

Buy

14.22%

Upside

Reiterated

09/12/25

AI Generated ArticleAI Generated Article

Andrew Fein

H.C. Wainwright

$194

Buy

30.34%

Upside

Reiterated

09/04/25

Biogen's Strategic Positioning and Potential Leadership in the Lupus Treatment Market

Myles Minter

William Blair

―

Buy

―

Reiterated

09/04/25

Biogen's Strategic Focus on Lupus Innovations and Pipeline Diversification Earns Buy RatingWe note that Biogen’s felzartamab, an anti-CD38 mAb, is being developed for lupus nephritis, among a host of kidney-related autoimmune indications. Felzartamab was discussed during the company’s investor day focused on CD38 biology earlier this year (see our recap note: Indications Underway). In addition, the company is developing an IRAK4 degrader (BIIB142) in undisclosed autoimmune indication(s) in collaboration with C4 Therapeutics (CCCC $2.56), which is in a Phase I clinical trial in healthy volunteers (NCT07133828) after recent IND acceptance. We note additional IRAK4 degrader molecules in clinical development for autoimmune indications from Gilead (GILD $112.99), Bristol Myers Squibb (BMS $47.50; Kymera (KYMR $43.30), among others.

Ami Fadia

Needham

―

Hold

―

Reiterated

09/04/25

Biogen's Stable Near-Term Outlook with Promising Long-Term Growth in Immunology Pipeline

Danielle Brill

Truist Financial

―

Hold

―

Reiterated

09/04/25

Biogen (BIIB) Gets a Hold from Truist Financial

David Amsellem

Piper Sandler

$118

Hold

-20.72%

Downside

Reiterated

09/04/25

Biogen (BIIB) Gets a Hold from Piper Sandler

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

09/03/25

We like the prospects for Biogen’s lupus pipeline, including Dapirolizumab pegol (DZP) and litifilimab, and given the encouraging data so far from both assets, we believe there is a fairly solid probability of success. And we agree with the company that lupus is a heterogenous disease and a large market opportunity with high unmet need and significant room for different therapeutic options with distinct MoAs and modalities. We look forward to the data for the multiple Phase 3 studies that should start to read out in 2H26 and help to validate the company’s pipeline restructuring and de-risking strategy. We remain Outperform.

Paul Matteis

Stifel Nicolaus

$175→$144

Hold

-3.25%

Downside

Reiterated

09/03/25

Biogen's Hold Rating: Balancing Long-Term Lupus Potential with Near-Term Alzheimer's Focus

Phil Nadeau

TD Cowen

$175

Buy

17.58%

Upside

Reiterated

09/03/25

TD Cowen Remains a Buy on Biogen (BIIB)

Salveen Richter

Goldman Sachs

$197

Buy

32.36%

Upside

Reiterated

09/02/25

Biogen's Competitive Edge: FDA Approval of Leqembi IQLIK Boosts Buy Rating

Terence Flynn

Morgan Stanley

$144

Hold

-3.25%

Downside

Reiterated

09/02/25

Cautious Outlook for Biogen Amid New Developments and Competitive Pressures

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Biogen (BIIB) Gets a Hold from Bernstein

Evan Seigerman

BMO Capital

$128

Hold

-14.00%

Downside

Reiterated

08/04/25

BMO Capital Sticks to Their Hold Rating for Biogen (BIIB)

Thomas Shrader

BTIG

―

Hold

―

Reiterated

08/04/25

Biogen's Mixed Prospects: Hold Rating Amid Growth and Technological Challenges

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sumant Kulkarni

Canaccord Genuity

$220

Buy

47.81%

Upside

Reiterated

09/12/25

Canaccord Genuity Keeps Their Buy Rating on Biogen (BIIB)Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $220.00 price target on Biogen (NASDAQ: BIIB).

Veda Pharmyne

TR | OpenAI - 4o

$152→$170

Buy

14.22%

Upside

Reiterated

09/12/25

AI Generated ArticleAI Generated Article

Andrew Fein

H.C. Wainwright

$194

Buy

30.34%

Upside

Reiterated

09/04/25

Biogen's Strategic Positioning and Potential Leadership in the Lupus Treatment Market

Myles Minter

William Blair

―

Buy

―

Reiterated

09/04/25

Ami Fadia

Needham

―

Hold

―

Reiterated

09/04/25

Biogen's Stable Near-Term Outlook with Promising Long-Term Growth in Immunology Pipeline

Danielle Brill

Truist Financial

―

Hold

―

Reiterated

09/04/25

Biogen (BIIB) Gets a Hold from Truist Financial

David Amsellem

Piper Sandler

$118

Hold

-20.72%

Downside

Reiterated

09/04/25

Biogen (BIIB) Gets a Hold from Piper Sandler

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

09/03/25

Paul Matteis

Stifel Nicolaus

$175→$144

Hold

-3.25%

Downside

Reiterated

09/03/25

Biogen's Hold Rating: Balancing Long-Term Lupus Potential with Near-Term Alzheimer's Focus

Phil Nadeau

TD Cowen

$175

Buy

17.58%

Upside

Reiterated

09/03/25

TD Cowen Remains a Buy on Biogen (BIIB)

Salveen Richter

Goldman Sachs

$197

Buy

32.36%

Upside

Reiterated

09/02/25

Biogen's Competitive Edge: FDA Approval of Leqembi IQLIK Boosts Buy Rating

Terence Flynn

Morgan Stanley

$144

Hold

-3.25%

Downside

Reiterated

09/02/25

Cautious Outlook for Biogen Amid New Developments and Competitive Pressures

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Biogen (BIIB) Gets a Hold from Bernstein

Evan Seigerman

BMO Capital

$128

Hold

-14.00%

Downside

Reiterated

08/04/25

BMO Capital Sticks to Their Hold Rating for Biogen (BIIB)

Thomas Shrader

BTIG

―

Hold

―

Reiterated

08/04/25

Biogen's Mixed Prospects: Hold Rating Amid Growth and Technological Challenges

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

1 Month

xxx

Success Rate

15/31 ratings generated profit

Average Return

+1.23%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 48.39% of your transactions generating a profit, with an average return of +1.23% per trade.

3 Months

xxx

Success Rate

16/31 ratings generated profit

Average Return

+0.16%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 51.61% of your transactions generating a profit, with an average return of +0.16% per trade.

1 Year

Marc GoodmanLeerink Partners

Success Rate

14/34 ratings generated profit

Average Return

-5.87%

reiterated a buy rating 10 days ago

Copying Marc Goodman's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -5.87% per trade.

2 Years

xxx

Success Rate

13/40 ratings generated profit

Average Return

-18.29%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 32.50% of your transactions generating a profit, with an average return of -18.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BIIB has received 32 Buy Ratings, 26 Hold Ratings, and 0 Sell Ratings. BIIB average Analyst price target in the past 3 months is 166.20.

Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.84 with a range of $2.85 to $4.60. The previous quarter’s EPS was $5.47. BIIB beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.86% of the time in the same period. In the last calendar year BIIB has Outperformed its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.34B with a range of $2.26B to $2.45B. The previous quarter’s sales results were $2.56B. BIIB beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 44.14% of the time in the same period. In the last calendar year BIIB has Outperformed its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?

Based on analyst ratings, Biogen’s 12-month average price target is 166.20.

What is BIIB’s upside potential, based on the analysts’ average price target?

Biogen has 11.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BIIB a Buy, Sell or Hold?

Biogen has a consensus rating of Moderate Buy which is based on 12 buy ratings, 14 hold ratings and 0 sell ratings.

What is Biogen’s price target?

The average price target for Biogen is 166.20. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $224.00 ,the lowest forecast is $118.00. The average price target represents 11.66% Increase from the current price of $148.84.

What do analysts say about Biogen?

Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.

How can I buy shares of BIIB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Biogen (BIIB) Stock Forecast & Price Target

BIIB Analyst Ratings

BIIB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biogen

BIIB Analyst Recommendation Trends

BIIB Financial Forecast

BIIB Earnings Forecast

BIIB Sales Forecast

BIIB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts